Increase walking speed and endurance
- Trial ID
- NCT06707402
- Official Title
- The Effects of 24 Weeks Community-based Brisk Walking on Physical Function, Comorbidities, Cognition, Disease Severity, and Health-related Quality of Life in People With Parkinson's Disease.
- Goal
- Increase walking speed and endurance
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University of Aarhus
- Study Type
- INTERVENTIONAL
- Enrollment
- 129 participants
- Conditions
- Parkinson Disease
- Interventions
- WALK, ACTIVE, CON
Plain-Language Summary
The goal is to find out whether a 24-week, community-based brisk walking program can improve walking ability, other health conditions, thinking, overall Parkinson's severity, and quality of life for people with Parkinson's. The approach uses regular brisk walking to raise heart rate, boost cardiovascular fitness, strengthen the muscles and neural circuits used for gait, and increase brain blood flow and growth factors that support cognition and motor control; it is meant to complement, not replace, medications like levodopa. The trial is looking for adults aged 40 and up with mild to moderate Parkinson's (Hoehn and Yahr stage 1,3) who report walking difficulties and can attend most sessions; people with dementia, major medical problems that prevent intense exercise, depression, pregnancy, alcohol abuse, or who already do frequent high-intensity brisk walking or use an activity tracker during exercise are excluded. The program runs for 24 weeks and aims to test real-world, group-based walking you can do in the community.
Locations
- Aarhus University, Department of Public Health, Sport Science, Aarhus C, Denmark
Frequently Asked Questions
- What is this trial testing?
- This trial is studying WALK. The goal is to find out whether a 24-week, community-based brisk walking program can improve walking ability, other health conditions, thinking, overall Parkinson's severity, and quality of life for people with Parkinson's. The approach uses regular brisk walking to raise heart rate, boost cardiovascular fitness, strengthen the muscles and neural circuits used for gait, and increase brain blood flow and growth factors that support cognition and motor control; it is meant to complement, not replace, medications like levodopa. The trial is looking for adults aged 40 and up with mild to moderate Parkinson's (Hoehn and Yahr stage 1,3) who report walking difficulties and can attend most sessions; people with dementia, major medical problems that prevent intense exercise, depression, pregnancy, alcohol abuse, or who already do frequent high-intensity brisk walking or use an activity tracker during exercise are excluded. The program runs for 24 weeks and aims to test real-world, group-based walking you can do in the community.
- Who can participate?
- Participants must be at least 40 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 5 months.